Despite these potential complications, Shavit-Stein and colleagues recently reported on PAR1 as a therapeutic target in familial ALS with studies using G93A SOD1 transgenic mice [119]. The gene discussed is MARK2; the disease is amyotrophic lateral sclerosis.